Browse the evidence

SGLT-2 inhibitors and GLP-1 receptor agonists (GLP-1RAs) lead to a decline in body weight ranging from 1.5 to 5 kg.

Practitioners can consider SGLT-2 inhibitors and GLP-1RAs as effective options for weight loss in patients.

Obesity is a major risk factor for the development and progression of type 2 diabetes.

Addressing obesity is crucial for managing type 2 diabetes.

Tirzepatide increases insulin secretion, reduces glucagon release, decreases fasting and postprandial glucose levels, promotes satiety, decreases body weight, and delays gastric emptying.

Tirzepatide can help manage blood sugar levels and weight in patients with type 2 diabetes.

The proportion of participants meeting the criteria for diabetes remission increased from 8.8% at baseline to 32.4% at 24 months.

A structured dietary intervention may enhance the likelihood of diabetes remission in T2DM patients.

Bariatric interventions resulted in reductions in body mass index and hemoglobin A1c.

Bariatric surgery can lead to improvements in metabolic health markers.

The LLHR group showed greater strength endurance increases (65 % 1RM) of 8 repetitions (95 % CI (2, 14)).

Lighter load training can effectively improve strength endurance in middle and older adults.

Tirzepatide significantly reduces body mass index, waist circumference, blood pressure, and atherosclerotic cardiovascular disease risk.

Tirzepatide may improve overall cardiometabolic health in non-diabetic obese patients.

A produce prescription program significantly improved HbA1c among low-income patients on Medicaid with poor glycemic control at baseline.

Implementing produce prescription programs may help improve glycemic control in low-income diabetic patients.

HbA1c at 6 months was significantly reduced in the intervention group compared to control.

The intervention may be effective in lowering HbA1c levels in similar patient populations.

Patients in the semaglutide group experienced greater weight loss compared to the control group (−8.2% vs. −4.6%; P <0.001).

Semaglutide may be effective for weight management in patients post-ablation.

Bariatric surgery effectively improves the management of obesity and inhibits the progression of multiple metabolic diseases.

Bariatric surgery should be considered as a viable option for managing obesity and related metabolic conditions.

Reductions in fat mass (FM) by 10% are associated with a lower risk of kidney outcomes (adjusted HR 0.80, 95% CI 0.69-0.94) in participants with overweight/obesity and type 2 diabetes mellitus (T2DM) in the intensive lifestyle intervention group.

Practitioners should consider promoting fat loss as a strategy to reduce kidney disease risk in patients with T2DM.

Reductions in waist circumference (WC) by 10% are associated with a lower risk of kidney outcomes (adjusted HR 0.72, 95% CI 0.59-0.88) in participants with overweight/obesity and T2DM in the intensive lifestyle intervention group.

Practitioners should encourage reductions in waist circumference to help lower kidney disease risk in T2DM patients.

After 5 weeks of a very low-calorie ketogenic diet (VLCKD), patients with Cushing's disease (CD) experienced a significant decrease in BMI (p=0.002), waist circumference (WC) (p=0.024), systolic (p=0.015) and diastolic blood pressure (p=0.005), ACTH (p=0.026), cortisone (p=0.025), total (p=0.006) and LDL cholesterol (p=0.017), triglycerides (p=0.016), alkaline phosphatase (p=0.008) and a significant increase in HDL cholesterol (p=0.017), vitamin D (p=0.015) and oral disposition index (Dio)(p=0.004).

Implementing a VLCKD may significantly improve metabolic health in patients with Cushing's disease.

A significant decrease in BMI (p=0.003), waist circumference (p=0.002), systolic (p=0.025) and diastolic blood pressure (p=0.007) and total cholesterol (p=0.026) and increase in HDL cholesterol (p=0.001) and oral disposition index (Dio)(p<0.001) was observed in controls after the diet.

A ketogenic diet may also benefit metabolic health in individuals without Cushing's disease.

The study confirms that a ketogenic diet is effective in improving metabolic disorders and can be combined with conventional therapy for Cushing's disease.

Combining a ketogenic diet with standard treatment may enhance metabolic outcomes in Cushing's disease patients.

GLP-1 receptor agonist patients experienced greater weight loss (7.8 kg) compared to controls (0.5 kg), with statistical significance (p<0.001).

Weight management strategies may be more effective in patients using GLP-1 receptor agonists.

Increased protein and energy intake is recommended during the preparatory phase to support muscle mass development.

Increase protein and energy intake during the preparatory phase for muscle development.

Semaglutide treatment led to a weight decrease of 16 kg and a 36% reduction in insulin dose after 6 months in a patient with type 1 diabetes.

Semaglutide may be a beneficial treatment option for weight management in patients with type 1 diabetes.

Delaying breakfast to 0930 or 1200 h is a low-cost strategy to improve glycaemic management in people with type 2 diabetes.

Healthcare providers can suggest delaying breakfast as a simple and cost-effective method for improving glycaemic control.

Modern dual and triple agonists achieve surgical-level metabolic benefits, redefining diabetes and obesity care.

These agonists may offer new treatment options for diabetes and obesity.

Endoscopic sleeve gastroplasty (ESG) has demonstrated durable weight loss, favorable safety, and superior cost-effectiveness compared to pharmacotherapy alone.

Practitioners may consider ESG as a viable option for patients seeking effective weight loss.

Semaglutide treatment resulted in significant reductions in body mass index (BMI), waist circumference, and HbA1c.

Practitioners can consider semaglutide as an effective treatment for reducing BMI and improving glycemic control in obese T2DM patients.

Bariatric surgery is the most effective treatment for patients with Type 2 diabetes mellitus (T2DM) and obesity.

Clinicians should consider bariatric surgery as a primary treatment option for patients with T2DM and obesity.